MTC selects R-One robot for future training

The Medical Training & Testing Center (MTC), a centre dedicated to training healthcare professionals, in Rouen will use Robocath’s R-One robot for future training with a special focus on new technologies.

Philippe Bencteux, MD, president and founder of Robocath, said: “This acquisition by the MTC of our first robotic solution is a key step in our company’s development. I am particularly proud of this collaboration. We share the same goal: to contribute to a new era of medical advances where robotics will definitely play a critical role.”

R-One is the first solution developed by Robocath which uses technology that optimises the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularising the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood.

R-One is designed to operate with precision and perform specific movements creating better interventional conditions. Currently at the approval stage, R-One commercialisation and clinical use will start in Europe in early 2019.

Véronique Desjardins, general manager of Rouen University Hospital Center, said: “The medical teams from the Rouen University Hospital Center were closely involved in the design of the R-One robot, due to the proximity of Robocath’s headquarters. This collaborative work within the ‘Rouen Innovation Santé’ working group shows that local collaborations can result in promising innovations for the benefit of healthcare practitioners and patients.

“Thanks to the financial support from the Rouen Normandy Metropole, the Rouen University Hospital Center was able to acquire the R-One device to complete MTC’s cutting-edge technical equipment offering. The robot will enable us to train future users of the platform. This fully aligns with our objective to support medical innovation and to bring these innovations to medical teams. Support for innovation and applied research is one of MTC’s goals, a centre that meets the needs of healthcare companies for testing of and training on the medical devices they develop."